Home › Funds › Propel Bio Management, LLC › MAZE
Propel Bio Management, LLC position in MAZE
MAZE THERAPEUTICS INC · Health Care
Propel Bio Management, LLC reported holding 191,998 shares of MAZE (MAZE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.2M, representing 2.77% of its reported portfolio and ranking #11 among its reported holdings. Propel Bio Management, LLC has disclosed MAZE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's MAZE position evolved
Propel Bio Management, LLC first disclosed a stake in MAZE in Q1 2026 at 43,798 shares (US$1.3M). The position peaked in Q3 2026 at 191,998 shares, worth US$5.2M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 191,998 shares valued at US$5.2M — an increase of 148,200 shares quarter over quarter.. Notable position changes include a 338% increase in Q3 2026 (shares rose 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 43.80K | $1.31M | New |
| Q2 2026 | 43.80K | $1.31M | Hold |
| Q3 2026 | 192.00K | $5.22M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MAZE and 13F data
MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MAZE
- Frazier Life Sciences Management, L.P. 5.03M sh · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M sh · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M sh · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M sh · $111.38M · Q2 2026
- Logos Global Management LP 1.94M sh · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M sh · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M sh · $47.80M · Q2 2026
- Alphabet Inc. 1.39M sh · $37.74M · Q3 2026
- BRAIDWELL LP 1.14M sh · $34.02M · Q2 2026
- Farallon Capital Management 1.11M sh · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M sh · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M sh · $30.91M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held MAZE?
Propel Bio Management, LLC has disclosed MAZE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in MAZE?
As of Q3 2026, Propel Bio Management, LLC holds 192.00K shares of MAZE (MAZE THERAPEUTICS INC), valued at $5.22M, representing 2.77% of its reported portfolio and ranking #11.
Has Propel Bio Management, LLC been buying or selling MAZE?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in MAZE. The position peaked in Q3 2026 at 192.00K shares.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.